ArticleTurkish journal of obstetrics and gynecology2025
Secretome improves anti-Müllerian hormone level and ovarian function in a premature ovarian insufficiency mice model.
Article in Turkish journal of obstetrics and gynecology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy of secretome in improving the anti-Müllerian hormone (AMH) level and ovarian weight and restoring ovarian function in the premature ovarian insufficiency (POI) model mice. Materials and Methods: A randomized, post-test-only control-group design was conducted on 18 mice, which were divided into three groups: A control group and two case groups injected with a secretome. Blood samples were analyzed for the AMH level with an enzyme-linked immunosorbent assay kit; ovarian weight was measured; and hematoxylin-eosin staining was used to measure and categorize follicles at each stage. Results: The cyclophosphamide (CTX) group showed significant differences in ovarian weight, AMH, and the numbers of primary, secondary, antral, and atretic follicles compared with the control group, indicating induction of premature ovarian failure. Follicular development was improved in the CTX-secretome group compared to the CTX group, with significantly increased ovarian weight and AMH, increased numbers of primary, secondary, and antral follicles, and decreased numbers of atretic follicles. However, the results showed a significant difference between the CTX-secretome and the control group. Conclusion: Our findings show that secretome therapy improved POI management, but the results have not yet restored normal ovarian function. It still does not achieve the same functional state as normal ovarian function. Further research, particularly involving different doses of secretome, is necessary to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.